ERBB2 and polyp: ERBB2-mutated SPs displayed increased risks of polyp recurrence, with a median polyp-free interval of 26 months compared to 32 months in wild-type SPs (P < 0.001; HR = 3.7; 95% CI = 2.3–6.0).